Phase 2, open-label, 1: 1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients …
A Ruzsa, M Sen, M Evans, LW Lee, K Hideghety… - Investigational new …, 2014 - Springer
Aim: to determine whether EMD 1201081, a TLR9 agonist, added to cetuximab had
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
antitumor activity in second-line recurrent/metastatic squamous cell carcinoma of the head …
Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed …
PURPOSE The phase III KEYNOTE-048 (ClinicalTrials. gov identifier: NCT02358031) trial of
pembrolizumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma …
pembrolizumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma …
[HTML][HTML] Immunotherapy breakthroughs in the treatment of recurrent or metastatic head and neck squamous cell carcinoma
C Borel, AC Jung, M Burgy - Cancers, 2020 - mdpi.com
Simple Summary Head and neck squamous cell carcinoma (HNSCC), in the locally
advanced setting, relapses in more than 50% of cases after surgery and/or chemo …
advanced setting, relapses in more than 50% of cases after surgery and/or chemo …
[HTML][HTML] First-line pembrolizumab±chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
S Takahashi, N Oridate, K Tanaka, Y Shimizu… - International Journal of …, 2022 - Springer
Background Here, we report the results of the Japanese subgroup of the phase 3 KEYNOTE-
048 study of pembrolizumab alone, pembrolizumab plus platinum and 5-fluorouracil …
048 study of pembrolizumab alone, pembrolizumab plus platinum and 5-fluorouracil …
FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after …
E Larkins, GM Blumenthal, W Yuan, K He… - The …, 2017 - academic.oup.com
Abstract On August 5, 2016, the US Food and Drug Administration granted accelerated
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth …
approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth …
Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055
R Haddad, T Seiwert, DG Pfister, F Worden… - Annals of …, 2016 - annalsofoncology.org
Background There are few treatment options in recurrent/metastatic (R/M) HNSCC after
progression on platinum and cetuximab, and their efficacy is disappointing. During …
progression on platinum and cetuximab, and their efficacy is disappointing. During …
[HTML][HTML] Cetuximab relative dose intensity (RDI) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): first observational prospective …
J Guigay, F Peyrade, B Petre-Lazar, F Mornex… - Annals of …, 2014 - Elsevier
Aim: Cetuximab combined with platinum is the standard first-line therapy in patients (pts)
with R/M SCCHN. DIRECT is the first multicenter prospective observational study evaluating …
with R/M SCCHN. DIRECT is the first multicenter prospective observational study evaluating …
LBA36 Nivolumab (N)+ ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M …
Background Despite recent tx advances in R/M SCCHN, durable survival benefit remains an
elusive goal. CheckMate 651 (NCT02741570), a phase 3 randomized trial, evaluated N+ I …
elusive goal. CheckMate 651 (NCT02741570), a phase 3 randomized trial, evaluated N+ I …
[HTML][HTML] Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous …
H Tanaka, T Enokida, S Okano, T Fujisawa… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall …
squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall …
[HTML][HTML] Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population …
HM Wang, PJ Lou, MH Yang, TH Chen, MY Lien… - Targeted Oncology, 2024 - Springer
Background Little is known regarding the association of cetuximab treatment beyond
progression (TBP) with survival among patients with recurrent or metastatic head and neck …
progression (TBP) with survival among patients with recurrent or metastatic head and neck …